P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS

Documenti analoghi

• Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
  di: Davidson Zhao, et al.
  Pubblicazione: (2023-03-01)
• Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort
  di: Xiaoxuan Lu, et al.
  Pubblicazione: (2026-01-01)
• Gilteritinib in an Isolated CNS Recurrence of FLT3‐ITD Positive AML
  di: Lina Susana Silva‐Bermudez, et al.
  Pubblicazione: (2026-01-01)
• Pandora’s Box of AML: How <i>TP53</i> Mutations Defy Therapy and Hint at New Hope
  di: Elyse A. Olesinski, et al.
  Pubblicazione: (2025-12-01)
• Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
  di: Jorge Cortes
  Pubblicazione: (2024-11-01)